Advances in pharmaceutical treatment options for narcolepsy

Authors:

Abstract
Introduction: Narcolepsy is a syndrome characterized by excessive daytime sleepiness (EDS), cataplexy, and other abnormal manifestations of rapid eye movement sleep phenomena. Since hypocretin deficiency is presumed to be the main pathophysiology of narcoleptic symptoms, hypocretin replacement therapy would be promising; small molecule hypocretin receptor agonists and intranasal administration of hypocretin peptides are recognized as potential pharmaceutical treatments. Pitolisant, a histaminergic inverse agonist, recently became available in European countries for the treatment of EDS. Additionally, other emerging treatments such as immunotherapies, TRH analogs, and solriamfetol have been under investigation. Areas covered: The pathophysiology of narcolepsy is summarized, along with the current and emerging pharmaceutical treatments for narcolepsy. Expert opinion: Hypocretin replacement therapy might be the most straightforward and effective treatment to address both cataplexy and EDS. Although small molecule synthetic hypocretin receptor agonists and intranasal hypocretin administration have been developed, for hypocretin receptor agonists, only preliminary data are available, and the efficacy data for intranasal delivery in human subjects are also lacking. Recently, the U.S. FDA has accepted the New Drug Application of solriamfetol for excessive sleepiness. It is likely that other emerging treatments will also become available in the clinical setting in the future.

This publication has 123 references indexed in Scilit: